Virginia Center Tapped to Scale 'Smart Bomb' Cancer Therapy Nationwide

FAIRFAX, Va. – June 04, 2026 – In a significant move to accelerate the adoption of a powerful new class of cancer treatments, Virginia Cancer Specialists (VCS) has been designated by the American Society for Radiation Oncology (ASTRO) as one of the first two national training centers for radiopharmaceutical therapy (RPT). This strategic initiative aims to dismantle a critical training bottleneck that has, until now, limited patient access to these highly targeted therapies across the United States.

The selection of the Fairfax-based practice, recently named the #1 cancer practice in Virginia for the third consecutive year, places it at the epicenter of a national effort to build a durable infrastructure for the future of precision oncology. By training other physicians, VCS will help scale a technology that has shown immense promise but has been hampered by a shortage of qualified practitioners.

The Human Capital Bottleneck in Precision Oncology

Radiopharmaceutical therapy, sometimes called radioligand therapy, represents a paradigm shift in cancer treatment. The therapy uses molecules engineered to seek out and bind to specific markers on cancer cells, delivering a potent, cell-killing radioactive payload directly to the tumor. This “smart bomb” approach minimizes damage to surrounding healthy tissue, a significant advantage over many traditional treatments.

Currently, RPT is most commonly used for metastatic castration-resistant prostate cancer and neuroendocrine tumors, but new agents and applications are emerging rapidly. The technology is here, and many oncology clinics are equipped to offer it. The problem hasn't been a lack of machinery, but a lack of certified human expertise.

To administer RPT, a physician must become a federally designated Authorized User (AU), a status that requires extensive supervised case experience. This has created a classic catch-22: to offer the therapy, you need training, but to get training, you need access to a mentor and a high volume of cases—a resource that has been critically scarce.

“ASTRO recognized a bottleneck that was limiting adoption and, ultimately, patient access,” said Youssef Charara, PhD, DABR, Chief Medical Physicist at Virginia Cancer Specialists. “The program was designed to close those gaps and provide an end-to-end, real-world framework for implementation.”

The challenge is not theoretical. When VCS launched its own RPT program back in 2014, its leaders experienced the barrier firsthand. It took the practice nearly a year to secure an Authorized User who could provide the necessary supervision to certify another physician. This lengthy, cumbersome process has been a major deterrent for practices nationwide, leaving a breakthrough therapy underutilized.

A Strategic Solution for National Scale

ASTRO’s new Authorized User Training Program, supported by an educational grant from Novartis, is designed to systematically solve this problem. Instead of a year-long search for a mentor, the program will allow qualified radiation oncologists to complete their supervised case requirements at a high-volume center like VCS, potentially in just a few days.

Virginia Cancer Specialists was chosen not just for its high patient volume, but for its deep, decade-long experience in the field. Having built its program from the ground up, the team possesses the practical and regulatory knowledge essential for mentorship. As an ASTRO-designated training center, VCS will provide visiting physicians with hands-on case experience, multidisciplinary guidance from its seasoned team of oncologists and physicists, and a practical roadmap for building a safe and compliant RPT program back in their own communities.

“This program addresses one of the most persistent challenges in radiopharmaceutical therapy: access to supervised training,” shared Dr. Harold C. Agbahiwe, a radiation oncologist at VCS. “By serving as an ASTRO-designated training center, we can help empower colleagues across the country to bring this important therapy to their communities safely and efficiently. It is a privilege to support this next chapter of precision cancer care.”

The Network Effect: Scaling a New Standard of Care

The designation is more than just an academic honor; it is a key strategic development that highlights the power of networked medicine. Virginia Cancer Specialists is a part of The US Oncology Network, a nationwide collaboration of over 2,700 physicians supported by healthcare giant McKesson. This affiliation provides the infrastructure and resources necessary to not only pioneer new treatments but also to disseminate that expertise at scale.

By serving as a training hub, VCS is effectively helping to decentralize advanced cancer care. Instead of forcing patients to travel to one of a handful of elite institutions, this model exports the knowledge, enabling more local and regional cancer centers to offer state-of-the-art therapies. This move transforms a leading regional practice into a national asset, leveraging its position within a powerful network to raise the standard of care across the country.

“Our multidisciplinary team has spent years building a safe, comprehensive program. Being chosen as a national training center validates that work and enables us to share our experience broadly,” said Dr. Gregory S. Sibley, also a radiation oncologist at the practice. “This initiative has the potential to dramatically expand patient access to targeted, effective treatments—and we are honored to play a role in that mission.”

From Early Adopter to National Standard-Bearer

For Virginia Cancer Specialists, this national appointment is the culmination of a long-term strategic commitment. The practice’s decision to invest in and navigate the complexities of RPT in 2014, long before it became a mainstream topic, has positioned it as a proven leader. Its robust clinical trials portfolio, including a joint venture with NEXT Oncology for Phase I trials and a 2024 partnership with the renowned Sara Cannon Research Institute, further cements its role as an organization on the cutting edge of cancer research and application.

Being recognized as the top cancer practice in its state by Castle Connolly Top Doctors for three years running speaks to its clinical excellence. Now, by taking on the role of a national educator, Virginia Cancer Specialists is not just treating patients but actively shaping the future of its field. This initiative will directly enable more physicians to become Authorized Users, ensuring that as new radiopharmaceutical agents are approved, a trained workforce is ready to deliver them to the patients who need them most.